Atrial fibrillation is one of the most common types of arrhythmia and is characterized by fast and irregular heart rhythms. The atria of patients suffering from the disease do not function properly. Atrial fibrillation can cause chest pain, heart failure, or stroke. The doctor needs to identify the first detected event of atrial fibrillation in a patient. The occurrence of two or more events of atrial fibrillation results in it being considered recurrent. In paroxysmal atrial fibrillation, the arrhythmia ends spontaneously, whereas in persistent atrial fibrillation the arrhythmia continues for more than a week. The first detected event of atrial fibrillation can either be paroxysmal or persistent. The patient can also experience many episodes of paroxysmal atrial fibrillation and random episodes of persistent atrial fibrillation. Permanent atrial fibrillation involves continuous episodes of atrial fibrillation and occurs when the patient and the doctor agree not to re-establish regular sinus rhythm by any means, either by catheter or surgical ablation.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

Atrial fibrillation

LAA closure devices

PART 05: Market landscape

Market overview

Five forces analysis

PART 06: Pipeline analysis

PART 07: Clinical trials

PART 08: Regulation of LAA closure devices

PART 09: Market segmentation by product type

Epicardial LAA closure device

Endocardial LAA closure device

PART 10: Market segmentation by end-user

Hospitals

ASCs

Heart clinics

PART 11: Geographical segmentation

LAA closure market in Americas

LAA closure market in EMEA

LAA closure market in APAC

PART 12: Market drivers

Increasing incidences of atrial fibrillation

Growing product approvals fueling market growth

Potential long-term cost-effectiveness associated with

use of LAA closure devices

Shift from open to MI surgeries

PART 13: Impact of drivers

PART 14: Market challenges

Increasing product recalls hindering growth prospects

High acceptance of warfarin and dabigatran

Stringent regulatory environment affecting product

approvals

Complications associated with LAA closure

procedures

PART 15: Impact of drivers and challenges

PART 16: Market trends

Emergence of 3D printing technology

Emergence of hybrid approach in LAA closure

techniques

Growing focus on clinical trials

Rising inorganic growth strategies

PART 17: Vendor landscape

Competitive scenario

Key news

M&A

PART 18: Key vendor analysis

AtriCure

Boston Scientific

Coherex Medical

St. Jude Medical

Other prominent vendors

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio